A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease

Expert Opinion on Pharmacotherapy
Anees Shajhan Ebrahem, Mark Oremus

Abstract

Alzheimer's disease (AD) results in progressively worsening cognitive decline, leading to loss of functional ability, behavior/mood disturbances, institutionalization, and death. Current pharmaceutical therapies only treat the symptoms of cognitive decline yet can be expensive for payers. Areas covered: The authors undertook a systematic review of economic evaluations of pharmaceutical therapies for AD. The literature search encompassed English-language studies indexed in PubMed (Medline), Cochrane Library Current, and Web of Science. The search included articles published between 1 January 1995 and 10 February 2018. The literature suggested AD medications generally dominated comparator treatments (e.g. placebo). Expert opinion: The authors noted several limitations of the included economic evaluations. These limitations suggest the results of the economic evaluations should be interpreted with caution. Many economic models were not transparent with respect to sources of probabilities and cost data, and data collected in certain jurisdictions were applied to other jurisdictions without considering the validity of such applications. Measuring health utilities in cognitively impaired populations raises questions about the validit...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jun 1, 1982·The British Journal of Psychiatry : the Journal of Mental Science·C P HughesR L Martin
Aug 8, 1998·International Journal of Geriatric Psychiatry·A StewartG Dempsey
May 14, 1999·Journal of the American Geriatrics Society·B J O'BrienS Gauthier
Jul 30, 2002·Dementia and Geriatric Cognitive Disorders·J Jaime CaroUNKNOWN AHEAD Study Group. Assessment of Health Economics in Alzheimer's Disease
Jul 16, 2003·Clinical Therapeutics·Kristen Migliaccio-WalleUNKNOWN AHEAD Study Group
Aug 2, 2003·International Journal of Geriatric Psychiatry·A WardUNKNOWN AHEAD Study Group
Oct 16, 2003·Dementia and Geriatric Cognitive Disorders·F FagnaniF Forette
Nov 14, 2003·Health and Quality of Life Outcomes·John HorsmanGeorge Torrance
Aug 25, 2004·Neurology·H FeldmanUNKNOWN Donepezil MSAD Study Investigators Group
Sep 1, 2005·The American Journal of Geriatric Pharmacotherapy·Linus Jönsson
May 4, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Fernando AntonanzasChantal Guilhaume
Apr 4, 2007·European Archives of Psychiatry and Clinical Neuroscience·Stefan J TeipelMichael Happich
May 24, 2007·Current Medical Research and Opinion·Derek WeyckerGerry Oster
May 24, 2007·International Journal of Geriatric Psychiatry·Jong-Ling Fuh, Shuu-Jiun Wang
Oct 25, 2007·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Micheline GagnonChantal Guilhaume
Jul 30, 2008·Journal of the American Geriatrics Society·John R Gilstad, Thomas E Finucane
Feb 11, 2009·Journal of Neurology, Neurosurgery, and Psychiatry·O L LopezS T Dekosky
Feb 18, 2009·Journal of Alzheimer's Disease : JAD·Julio López-BastidaRenata Linertová
Jun 2, 2009·Archives of Gerontology and Geriatrics·Masashi Kasuya, Kenichi Meguro
Dec 1, 2003·Expert Review of Pharmacoeconomics & Outcomes Research·Anders Wimo
May 28, 2010·Journal of Medical Economics·B RiveC François
Oct 22, 2011·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Jean LachaineSébastien Bineau
Aug 10, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Jacques TouchonSébastien Bineau
Jan 21, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Mark OremusParminder Raina
Jun 19, 2014·Journal of Child Health Care : for Professionals Working with Children in the Hospital and Community·Murray Drummond, Claire Drummond
Jan 4, 2015·BMJ : British Medical Journal·Larissa ShamseerUNKNOWN PRISMA-P Group
Jun 5, 2015·PharmacoEconomics·Nalin PayakachatJ Mick Tilford
Nov 21, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Charles Christian AdarkwahSilvia M A A Evers

❮ Previous
Next ❯

Citations

Sep 22, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Anders GustavssonRobin Thompson
Aug 20, 2021·The Journal of Nutrition, Health & Aging·J E Morley

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.